High Quality 99% Brivaracetam CAS 357336-20-0 Powder Fast Shipping Good Price
2 Inquiries
357336-20-0
Pharmaceutical Grade
99.5%
Hangzhou
HyperChem
1kg/Bag
Yes
2025-01-05
Pharmaceuticals,Peptide,Cosmetics,Nutritional Supplements
-
Product Description
-
Seller Information
-
Inquiry History
-
DescriptionECHEMI Editorial ReferenceChEBI: A non-proteinogenic amino acid derivative that is butanamide in which the pro-S hydrogen at position 2 is replaced by a (4R)-2-oxo-4-propylpyrrolidin-1-yl. Used for treatment of partial onset seizures related to epilepsy.
Brivaracetam is a non-proteinogenic amino acid derivative that is butanamide in which the pro-S hydrogen at position 2 is replaced by a (4R)-2-oxo-4-propylpyrrolidin-1-yl. Used for treatment of partial onset seizures related to epilepsy. It has a role as an anticonvulsant. It is a gamma-lactam and a non-proteinogenic amino acid derivative. It derives from a L-alpha-aminobutyric acid.|Brivaracetam is a DEA Schedule V controlled substance. Substances in the DEA Schedule V have a low potential for abuse relative to substances listed in Schedule IV and consist primarily of preparations containing limited quantities of certain narcotics.|Brivaracetam is a racetam derivative of levetiracetam used in the treatment of partial-onset seizures. Brivaracetam binds SV2A with 20 times higher affinity than levetiracetam. It is available under the brand name Briviact made by UCB. Briviact received FDA approval on February 19, 2016.|The mechanism of action of brivaracetam is as an Epoxide Hydrolase Inhibitor.|Brivaracetam is a relatively unique anticonvulsant that is typically used in combination with other antiepileptic medications for partial onset seizures. Brivaracetam has been linked to rare instances of serum aminotransferase and alkaline phosphatase elevations during treatment and is suspected of causing rare cases of clinically apparent drug induced liver disease.|Brivaracetam is an orally bioavailable levetiracetam derivative, with anticonvulsant activity. Although the exact mechanism through which brivaracetam exerts its effects is not fully known, this agent targets and binds to synaptic vesicle protein 2A (SV2A) in the brain. This prevents synaptic vesicle exocytosis and the synaptic release of certain, as of yet not fully known, excitatory neurotransmitters. This may inhibit impulse conduction across synapses, decrease neuronal (hyper-)excitability, and may modulate epileptogenesis. SV2A, a membrane glycoprotein present in neuronal synaptic vesicles, plays a key role in action potential-induced neurotransmitter release in the brain.Basic Info-
Product Name:
Brivaracetam
Other Name:1-Pyrrolidineacetamide,α-ethyl-2-oxo-4-propyl-,(αS,4R)-;(αS,4R)-α-Ethyl-2-oxo-4-propyl-1-pyrrolidineacetamide;UCB 34714;Brivaracetam;Briviact;1-Pyrrolidineacetamide α-ethyl-2-oxo-4-propyl-,(αS,4R)-;(2S)-2-[(4R)-2-Oxo-4-propyl-1-pyrrolidinyl]butanamide;2375745-81-4
CAS No.:357336-20-0
Molecular Formula:C11H20N2O2
InChIKeys:InChIKey=MSYKRHVOOPPJKU-BDAKNGLRSA-N
Molecular Weight:703.83
Exact Mass:212.29
EC Number:1592732-453-0
UNII:U863JGG2IA
DEA Code Number:2710
NCI Thesaurus Code:C65270
ATC Code:N03AX23|N - Nervous system
HScode:2933990090
Categories:
Characteristics-
PSA:
63.4
XLogP3:0.88
Density:1.062
Melting Point:76.38°
Boiling Point:409.3±28.0 °C at 760 mmHg
Flash Point:201.3±24.0 °C
Refractive Index:1.494
Specific rotation:D25 -60.57° (c = 1 in methanol)
Hazard IdentificationClassification of the substance or mixture
Acute toxicity - Category 4, Oral
GHS label elements, including precautionary statements
Pictogram(s)
Signal word Warning
Hazard statement(s) H302 Harmful if swallowed
Precautionary statement(s) Prevention P264 Wash ... thoroughly after handling.
P270 Do not eat, drink or smoke when using this product.
Response P301+P317 IF SWALLOWED: Get medical help.
P330 Rinse mouth.
Storage none
Disposal P501 Dispose of contents/container to an appropriate treatment and disposal facility in accordance with applicable laws and regulations, and product characteristics at time of disposal.
Other hazards which do not result in classification
no data available
Handling and StoragePrecautions for safe handling
Handling in a well ventilated place. Wear suitable protective clothing. Avoid contact with skin and eyes. Avoid formation of dust and aerosols. Use non-sparking tools. Prevent fire caused by electrostatic discharge steam.
Conditions for safe storage, including any incompatibilities
Store the container tightly closed in a dry, cool and well-ventilated place. Store apart from foodstuff containers or incompatible materials.
-
-
Seller Information
-
Business Type:
Trader
-
Main Products:
Pharmaceuticals,Peptide,Cosmetics,Nutritional Supplements
-
Location:
Rm. 803, Tower 4, LOFT49 Creative City Pioneer Zone, No.88 Jiru Rd. Gongshu Dist., Hangzhou, 310015 ZJ, China
-
Payment Terms:
TT against copy of documents,D/P,L/C,D/A,O/A,TT against B/L draft before shipment,100% TT in advance
-
Average lead Time:
10 days
-
Total Annual Revenue:
$5 million-$10 million
-
Total Employees:
11-50
-
Year of Establishment:
2013
Company Certificates-
Certification Report by Bureau Veritas
-
-
Inquiry History2 Inquiries
Country Product Purchase Quantity Date Posted
India
brivaracetam
100 KG Jul 30, 2026
India
Brivaracetam
1 KG Sep 24, 2024 Post an enquiry for this product
- Hot Searches
- inj methylene blue
- prednisolone vs prednisolone sodium phosphate
- aluminum ammonium sulfate
- imidazol
- acetic acid bulk
- benzalkonium chloride purchase
- calcium sulfate dihydrate
- research chemical website
- glycol price
- enterobacter cloacae.
- ammonia price index
- retatrutide peptide buy usa price
More from this Seller
-
-
-
99% High purity Memantine Power Pharmacy Grade
Pharmaceutical Grade / 99%
-
-
-
-
Anticancer API 99% TYRA-300/TYRA 300/Dabogratinib CAS:2800223-30-5 for R&D
Pharmaceutical Grade / 99.9%
$1500-1800/G FOB
-
-
-
-
raw material Sodium Silicate
Industrial Grade / 99%
-
-
-
-
raw material L-Valine
Pharmaceutical Grade / 99%
-